Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study.
Sign Up to like & getrecommendations! Published in 2022 at "Allergy and asthma proceedings"
DOI: 10.2500/aap.2022.43.220068
Abstract: Background: There are no well-defined data that help predict the recurrence risk of urticaria after omalizumab cessation in elderly patients with chronic spontaneous urticaria (CSU). Objective: We aimed to evaluate the effectiveness and safety of… read more here.
Keywords: omalizumab cessation; cessation elderly; group; igg anti ... See more keywords